Paris - Delayed Quote EUR

ABIONYX Pharma SA (ABNX.PA)

1.1980

+0.0120

+(1.01%)

At close: 5:35:03 PM GMT+2

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

PARIS, April 03, 2025--Regulatory News: ABIONYX Pharma (Paris:ABNX):

Business Wire 13 days ago

ABNX.PA
+1.01%
3 European Penny Stocks With Market Caps Over €30M

As the pan-European STOXX Europe 600 Index has recently edged higher, buoyed by hopes of increased government spending yet tempered by trade tensions, investors are keenly observing opportunities within the market. Penny stocks, a term that may seem outdated but remains relevant in highlighting smaller or less-established companies, can offer significant value when supported by strong financials. By focusing on those with robust balance sheets and potential for growth, investors may uncover...

Simply Wall St. 21 days ago

ABNX.PA
+1.01%
CIC Market Solutions Initiates Buy Coverage of ABIONYX Pharma

TOULOUSE, France & LAKELAND, Mich., March 21, 2025--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), next-generation biopharma dedicated to the development of innovative biomedicines based on recombinant apolipoprotein apoA-I for the treatment of the most severe inflammatory diseases, today announced that CIC Market Solutions, part of Crédit Mutuel Alliance Fédérale, one of Europe's leading banking groups, has initiated coverage of its stock.

Business Wire 27 days ago

ABNX.PA
+1.01%
ABIONYX Pharma: Availability of the Universal Registration Document for the Year 2024

TOULOUSE, France & LAKELAND, Mich., March 17, 2025--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a next generation biopharma company dedicated to the development of innovative biomedicines based on a recombinant apolipoprotein apoA-1 for the treatment of the most severe inflammatory diseases, announces that it has filed with the "Autorité des Marchés Financiers" (AMF) its Universal Registration Document for the year ended December 31, 2024, dated March 14, 2025.

Business Wire 30 days ago

ABNX.PA
+1.01%
ABIONYX Pharma Announces Its 2024 Full-Year Results

TOULOUSE, France & LAKELAND, Mich., March 05, 2025--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a next generation biopharma company dedicated to the development of innovative biomedicines based on a recombinant apolipoprotein apoA-1 for the treatment of the most severe inflammatory diseases, today reports its 2024 full-year results as approved by the Board of Directors at its meeting of March 4, 2025. The audit procedures on the consolidated accounts have been

Business Wire last month

ABNX.PA
+1.01%
World Rare Disease Day: ABIONYX renews its commitment to treat LCAT Deficiency (Norum's disease) and provides an update on its advances

TOULOUSE, France & LAKELAND, Mich., February 28, 2025--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a next generation biopharma company dedicated to the development of innovative biomedicines based on a recombinant apolipoprotein apoA-1 for the treatment of the most severe inflammatory diseases, today provides an update on its progress and confirms its commitment to the rare disease known as LCAT Deficiency or ‘Norum's disease’.

Business Wire last month

ABNX.PA
+1.01%
ABIONYX Pharma Provides an Update on Its Business and Cash Position for the 4th Quarter of 2024

TOULOUSE, France & LAKELAND, Mich., February 27, 2025--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a next generation biopharma company dedicated to the development of innovative biomedicines based on a recombinant apolipoprotein apoA-1 for the treatment of the most severe inflammatory diseases, today provides an update on its business and its cash position as of December 31, 2024.

Business Wire last month

ABNX.PA
+1.01%
Cemat Leads The Charge In European Penny Stocks

As the European markets display cautious optimism amid ongoing geopolitical developments and trade policy changes, investors are keenly observing potential opportunities. Penny stocks, often seen as a niche investment area, continue to offer intriguing prospects for those willing to explore smaller or newer companies. Despite being an outdated term, penny stocks can provide growth potential when they boast strong financial health and fundamentals.

Simply Wall St. last month

ABNX.PA
+1.01%
CEMAT.CO

GOMX.ST
ABIONYX Pharma, winner of the France 2030 Plan’s "i-Démo" call for projects, awarded €8.7 million from the French government to fight against Sepsis, the 3rd leading cause of death worldwide

TOULOUSE, France & WESTLAKE, Calif., February 20, 2025--ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces today that its clinical development in sepsis has been selected as part of the "i-Démo" call for projects under the France 2030 plan, operated by Bpifrance on behalf of the French government.

Business Wire last month

ABNX.PA
+1.01%
ABIONYX Pharma Announces Its Financial Calendar for the Year 2025

TOULOUSE, France & LAKELAND, Mich., January 13, 2025--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today announces its financial calendar for 2025.

Business Wire 3 months ago

ABNX.PA
+1.01%
ABIONYX Pharma announces the approval of all resolutions put to the vote at its Combined General Meeting on November 28, 2024

TOULOUSE, France & LAKELAND, Mich., November 29, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces that all resolutions presented at its Combined General Meeting on November 28th, 2024, were approved.

Business Wire 4 months ago

ABNX.PA
+1.01%
ABIONYX Pharma Provides an Update on Its Business and Cash Position for the Third Quarter of 2024

TOULOUSE, France & LAKELAND, Mich., November 14, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the recombinant human apolipoprotein apoA-I, today provides an update on its business and its cash position as of September 30, 2024.

Business Wire 4 months ago

ABNX.PA
+1.01%
ABIONYX Pharma Announces the Main Resolutions Proposed at the Next Combined General Meeting on November 28, 2024, and the Availability of Related Documents

TOULOUSE, France & LAKELAND, Mich., November 07, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today informs its shareholders that its Combined General Meeting (Ordinary and Extraordinary) will be held on November 28, 2024 at 2 pm at the Company's head office at 33-43 avenue Georges Pompidou Bât. D - 31130

Business Wire 5 months ago

ABNX.PA
+1.01%
ABIONYX Pharma RACERS Study Clinical Results in Brain-Fog Selected for Poster Presentation at the American Society of Nephrology (ASN) 2024 Annual Meeting "Kidney Week"

TOULOUSE, France & LAKELAND, Mich., October 24, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today announced that the Company’s Phase 2b RACERS study in sepsis has been selected again as a poster presentation in the "AKI: Clinical, Outcome, and Trials- Epidemiology and Pathophysiology" poster session at t

Business Wire 5 months ago

ABNX.PA
+1.01%
ABIONYX Pharma Received Positive Feedback from the EMA for CER-001 in LCAT Deficiency

TOULOUSE, France & LAKELAND, Mich., October 21, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, has submitted on July 11, 2024, a formal Application for scientific advice to the European Medicines Agency (EMA) for recombinant human apolipoprotein A-I, CER-001, for treatment of lecithin-cholesterol acyltransferas

Business Wire 5 months ago

ABNX.PA
+1.01%
ABIONYX Pharma Announces Its 2024 Half-Year Financial Results

TOULOUSE, FRANCE & LAKELAND, Mich., September 26, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant apoA-1, today announces its financial results for the first half of 2024.

Business Wire 6 months ago

ABNX.PA
+1.01%
ABIONYX Pharma provides an update on its business and cash position for the 1st half of 2024

TOULOUSE, France & LAKELAND, Mich., August 22, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announced today its cash position for the 1st half to June 30, 2024, and the highlights of the period.

Business Wire 7 months ago

ABNX.PA
+1.01%
ABIONYX Carries out Successfully a Capital Increase With Cancellation of Preferential Subscription Rights for the Benefit of a Category of Persons Through the Issue of Shares With Warrants for an Amount of c.€3.4 Million

TOULOUSE, France & LAKELAND, Mich., July 01, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces the success of a capital increase with cancellation of preferential subscription rights for the benefit of a category of persons for an amount of close to €3.4 million through the issue of a maximum number

Business Wire 9 months ago

ABNX.PA
+1.01%
ABIONYX Pharma announces unanimous approval of all resolutions put to the vote at its Combined General Meeting

TOULOUSE, France & LAKELAND, Mich., June 27, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces that all resolutions presented at its Combined General Meeting were unanimously approved.

Business Wire 9 months ago

ABNX.PA
+1.01%
ABIONYX decides on a capital increase with cancellation of preferential subscription rights for the benefit of a category of persons through the issue of shares with warrants for an amount of c.€3.4 million

TOULOUSE, France & LAKELAND, Mich., June 19, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces the launch of a capital increase with cancellation of preferential subscription rights for the benefit of a category of persons for an amount of close to €3.4 million through the issue of a maximum number o

Business Wire 9 months ago

ABNX.PA
+1.01%

Performance Overview

Return	ABNX.PA	CAC 40 (^FCHI)
YTD	+0.67%	-1.29%
1-Year	+9.51%	-8.72%
3-Year	-41.42%	+10.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ABIONYX Pharma SA (ABNX.PA)

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

3 European Penny Stocks With Market Caps Over €30M

CIC Market Solutions Initiates Buy Coverage of ABIONYX Pharma

ABIONYX Pharma: Availability of the Universal Registration Document for the Year 2024

ABIONYX Pharma Announces Its 2024 Full-Year Results

World Rare Disease Day: ABIONYX renews its commitment to treat LCAT Deficiency (Norum's disease) and provides an update on its advances

ABIONYX Pharma Provides an Update on Its Business and Cash Position for the 4th Quarter of 2024

Cemat Leads The Charge In European Penny Stocks

ABIONYX Pharma, winner of the France 2030 Plan’s "i-Démo" call for projects, awarded €8.7 million from the French government to fight against Sepsis, the 3rd leading cause of death worldwide

ABIONYX Pharma Announces Its Financial Calendar for the Year 2025

ABIONYX Pharma announces the approval of all resolutions put to the vote at its Combined General Meeting on November 28, 2024

ABIONYX Pharma Provides an Update on Its Business and Cash Position for the Third Quarter of 2024

ABIONYX Pharma Announces the Main Resolutions Proposed at the Next Combined General Meeting on November 28, 2024, and the Availability of Related Documents

ABIONYX Pharma RACERS Study Clinical Results in Brain-Fog Selected for Poster Presentation at the American Society of Nephrology (ASN) 2024 Annual Meeting "Kidney Week"

ABIONYX Pharma Received Positive Feedback from the EMA for CER-001 in LCAT Deficiency

ABIONYX Pharma Announces Its 2024 Half-Year Financial Results

ABIONYX Pharma provides an update on its business and cash position for the 1st half of 2024

ABIONYX Carries out Successfully a Capital Increase With Cancellation of Preferential Subscription Rights for the Benefit of a Category of Persons Through the Issue of Shares With Warrants for an Amount of c.€3.4 Million

ABIONYX Pharma announces unanimous approval of all resolutions put to the vote at its Combined General Meeting

ABIONYX decides on a capital increase with cancellation of preferential subscription rights for the benefit of a category of persons through the issue of shares with warrants for an amount of c.€3.4 million

Performance Overview